Novo Nordisk's closely watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the ...

When women taking weight loss jabs stop their use because of pregnancy, the rebound weight gain brings health risks for their ...

GLP-1 medicines, such as tirzepatide (Mounjaro) and semaglutide (Wegovy) work by making people feel fuller for longer ...

FAT jabs could harm mum and baby if taken too close to pregnancy, a study suggests. Women who used the GLP-1 injections, such ...

People taking certain weight loss injections could be at risk of a wide variety of side effects, some of which may even ...

Four in five people put the weight back on after coming of weight loss jabs, new research has suggested today-and they're not ...

People taking certain weight loss injections could be at risk of a wide variety of side effects, some of which may even ...

The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

The surge in usage of 'GLP-1'-style weight loss medications is seeing a "ripple effect" begin to unfold, impacting eating patterns in a number of ...

An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...

The oral version of Rybelsus failed to meet its primary goal in two late-stage clinical trials, which aimed to evaluate its ...

The results from the two trials of early-stage patients, called EVOKE and EVOKE+, are another setback for the Danish drugmaker and new CEO Mike Doustdar, which had seen booming success, driven by ...